Urotensin II in cardiovascular regulation

Vascular Health and Risk Management

Volumn 4, Issue 4, 2008, Pages 775-785

  Russell, Fraser D ^a  

^a UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

Cardiovascular disease; Heart failure; Hypertension; Urotensin II

Indexed keywords

ACT 058362; AMINO ACID; CARDIOVASCULAR AGENT; G PROTEIN COUPLED RECEPTOR; HORMONE; ISOPRENALINE; NEUROTRANSMITTER; NITROPRUSSIDE SODIUM; PALOSURAN; SB 611812; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR ANTAGONIST;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG ABSORPTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; NONHUMAN; PREECLAMPSIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RESTENOSIS; REVIEW; STREPTOZOCIN DIABETES; TISSUE LEVEL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UROTENSINS;

EID: 52249113281     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Affolter JT, Newby DE, Wilkinson IB, et al. 2002. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol, 54:617-21.
2. Aiyar N, Guida B, Ao Z, et al. 2004. Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays. Peptides, 25:1339-47.
3. Alpert JS, Antman E, Apple F, et al. 2000. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee or the Redefinition of Myocardial Infarction. J Am Coll Cardiol, 36:959-69.
4. Ames RS, Sarau HM, Chambers JK, et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401:282-6.
5. Balat O, Aksoy F, Kutlar I, et al. 2005. Increased plasma levels of urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol, 120:33-8.
6. Behm DJ, Harrison SM, Ao Z, et al. 2003. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol, 139:464-72.
7. Böhm F, Pernow J. 2002. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol, 135:25-7.
8. Bottrill FE, Douglas SA, Hiley CR, et al. 2000. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol, 130:1865-70.
9. Bousette N, Hu F, Ohlstein EH, et al. 2006a. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol, 41:285-95.
10. Bousette N, Patel L, Douglas SA, et al. 2004. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176:117-23.
11. Bousette N, Pottinger J, Ramli W, et al. 2006b. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodelling in experimental ischemic heart disease. Peptides, 27:2919-26.
12. Charles CJ, Rademaker MT, Richards AM, et al. 2005. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides, 26:2211-14.
13. Cheung BMY, Leung R, Man YB, et al. 2004. Plasma concentration of urotensin II is raised in hypertension. J Hypertens, 22:1341-4.
14. Clozel M, Binkert C, Birker-Robaczewska M, et al. 2004. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(-benzyl-4-hydroxy-piperidin-l-yl)-ethyl]-3-(2-methyl-quinolin-4- yl)-urea sulfate salt): First demonstation of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther, 311:204-12.
15. Clozel M, Hess P, Qiu C, et al. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther, 316:1115-21.
16. Coulouarn Y, Lihrmann I, Jegou S, et al. 1998. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 95:15803-8.
17. Douglas SA, Dhanak D, Johns DG. 2004a. From "gills to pills": urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci, 25:76-85.
18. Douglas SA, Naselsky D, Ao Z, et al. 2004b. Identification and phar- macological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol, 142:921-32.
19. Douglas SA, Tayara L, Ohistein EH, et al. 2002. Congestive heart failure and expression of myocardial urotensin II. Lancet, 359:1990-7.
20. Dschietzig T, Bartsch C, Pregla R, et al. 2002. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Reg Peptides, 110:33-8.
21. Dschietzig T, Richter C, Bartsch C, et al. 2001. Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun, 289:245-51.
22. Fontes-Sousa AP, Brás-Silva C, Pires AL, et al. 2007. Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn-Schmied Arch Pharmacol, 376:107-15.
23. Gardiner SM, March JE, Kemp PA, et al. 2006. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol, 147:612-21.
24. Giebing G, Tölle M, Jügensen J, et al. 2005. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res, 97:707-15.
25. Gold SJ, Thompson JP, Williams JP, et al. 2007. Does cigarette smoking increase plasma urotensin II concentrations? Eur J Clin Pharmacol, 63:253-7.
26. Gong H, Wang Y-X, Zhu Y-Z, et al. 2004. Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol, 97:2228-35.
27. Gray, GA, Jones MR, Sharif I, 2001. Human urotensin II increases coronary perfusion pressure in the isolated rat heart. Potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci, 69:175-80.
28. Gruson D, Rousseau MF, Ahn SA, et al. 2006. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides, 27:1527-31.
29. Hassan GS, Douglas SA, Ohlstein EH, et al. 2005. Expression of urotensin-II in human coronary atherosclerosis. Peptides, 26:2464-72.
30. Heller J, Schepke M, Neef M, et al. 2002. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol, 37:767-72.
31. Hillier C, Berry C, Petrie MC, et al. 2001. Effects of urotensin II in human arteries and veins of varying calibre. Circulation, 103:1378-81.
32. Hishikawa K, Nakaki T, Marumo T, et al. 1995. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension, 25:449-452.
33. Ishihata A, Ogaki T, Aita T, et al. 2005. Role of prostaglandins in urotensin II-induced vasodilation in the coronary arteries of aged rats. Eur J Pharmacol, 523:119-26.
34. Joyal D, Huynh T, Aiyar N, et al. 2006. Urotensin II levels in acute coronary syndromes. Int J Cardiol, 108:31-5.
35. Katano Y, Ishihata A, Aita T, et al. 2000. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol, 402:209-11.
36. Kemp W, Krum H, Colman J, et al. 2007. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Internat, 27:1232-9.
37. Khan SQ, Bhandari SS, Quinn P, et al. 2007. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol, 117:323-9.
38. Krüger S, Graf J, Kunz D, et al. 2005. Urotensin II in patients with chronic heart failure. Eur J Heart Failure, 7:475-8.
39. Lacza Z, Busija DW. 2006. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci, 78:2763-6.
40. Lambert DG. 2007. Urotensin II: from osmoregulation in fish to cardiovascular regulation in man. Br J Anaesthesia, 98:557-9.
41. Langham RG, Kelly DJ, Gow RM, et al. 2004. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kid Dis, 44:826-31.
42. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. 2004. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol, 94:93-7.
43. Lim M, Honisett S, Sparkes CD, et al. 2004. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation, 109:1212-4.
44. MacLean MR, Alexander D, Stirrat A, et al. 2000. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol, 130:201-4.
45. Maguire JJ, Kuc RE, Davenport AP. 2000. Orphan-receptor ligand human urotensin II: receptor localization in human tisues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol, 131:441-6.
46. Maguire JJ, Kuc RE, Wiley KE, et al. 2004. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 25:1767-74.
47. Mallamaci F, Cutrupi S, Pizzini P, et al. 2005. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol, 18:727-32.
48. Mallamaci F, Cutrupi S, Pizzini P, et al. 2006. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens, 19:505-10.
49. Matsushita M, Shichiri M, Imai T, et al. 2001. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens, 19:2185-90.
50. McDonald J, Batuwangala M, Lambert DG. 2007. Role of urotensin II and its receptor in health and disease. J Anesth, 21:378-89.
51. 2+] transient: normal vs CHF. Circulation, 106(Suppl II):II-26.
52. Mosenkis A, Danoff TM, Aiyar N, et al. 2007. Human urotensin II in the plasma of anephric subjects. Nephrol Dial Transplant, 22:1269-70.
53. Ng LL, Loke I, O'Brien RJ, et al. 2002. Plasma urotensin in human systolic heart failure, Circulation, 106:2877-80.
54. Nothacker H-P, Wang Z, McNeill AM, et al. 1999. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nature Cell Biol, 1:383-5.
55. Onan D, Pipolo L, Yang E, et al. 2004. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol, 18:2344-54.
56. Rakowski E, Hassan GS, Dhanak D, et al. 2005. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol, 39:785-91.
57. Richards AM, Nicholls MG, Lainchbury JG, et al. 2002. Plasma urotensin II in heart failure. Lancet, 360:545-6.
58. Russell FD. 2004. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther, 103:223-43.
59. Russell FD, Kearns P, Toth I, et al. 2004. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther, 310:209-14.
60. Russell FD, Meyers D, Galbraith AJ, et al. 2003. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol, 285:H1576-81.
61. Russell FD, Molenaar P. 2004. Investigation of signalling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res, 63:673-81.
62. Russell FD, Molenaar P, O'Brien DM. 2001. Cardiostimulant effects of urotensin-II in human heart in vitro, Br J Pharmacol, 132:5-9.
63. Sauzeau V, Le Mellionnec E, Bertoglio J, et al. 2001. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res, 88:1102-4.
64. Shenouda A, Douglas SA, Ohlstein EH, et al. 2002. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem, 50:885-9.
65. Sidharta PN, van Giersbergen PLM, Schaarschmidt D, et al. 2005. Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects. Br J Clin Pharmacol, 60:677-8.
66. Sidharta PN, Wagner FD, Bohnemeier H, et al. 2006. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther, 80:246-56.
67. Sondermeijer B, Kompa A, Komesaroff P, et al. 2005. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens, 18:1195-9.
68. Stirrat A, Gallagher M, Douglas SA, et al. 2001. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol, 280:H925-8.
69. Sugo T, Murakami Y, Shimomura Y, et al. 2003. Identification of urotensin-II-related peptide as the urotensin II-immunoreactive molecule in rat brain. Biochem Biophys Res Commun, 310:860-8.
70. Suguro T, Watanabe T, Ban Y, et al. 2007. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens, 20:211-17.
71. Takahashi K, Totsune K, Murakami O, et al. 2001. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides, 22:1175-9.
72. Thompson JP, Watt P, Sanghavi S, et al. 2003. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg, 97:1501-3.
73. Totsune K, Takahashi K, Arihara Z, et al. 2001. Role of urotensin II in patients on dialysis. Lancet, 358:810-11.
74. Totsune K, Takahashi Y, Arihara Z, et al. 2003. Increased plasma urote II levels in patients with diabetes mellitus. Clin Sci, 104:1-5.
75. Tsutamoto T, Wada A, Maeda Y, et al. 1994. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients chronic heart failure. J Am Coll Cardiol, 23:1427-33.
76. Tzanidis A, Hannan RD, Thomas WG, et al. 2003. Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ Res, 93:246-53.
77. Wagner OF, Christ G, Wojta J, et al. 1992. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem, 267:16066-8.
78. Wang D, Iversen J, Wilcox CS, et al. 2003. Endothelial dysfunction reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kid Internat, 64:1381-8.
79. Watanabe T, Kanome T, Miyazaki A, et al. 2006b. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res, 29:375-87.
80. Watanabe T, Takahashi K, Kanome T et al. 2006a. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res, 29:821-31.
81. Wilkinson IB, Affolter JT, de Haas SL, et al. 2002. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res, 53:341-7.
82. Yoshimoto S, Ishizaki Y, Sasaki T, et al. 1991. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke, 22:378-83.
83. Zhang AY, Chen Y-F, Zhang DX, et al. 2003. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol, 285:F792-8.
84. Zhang Y-G, Li Y-G, Liu B-G, et al. 2007, Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin, 28:36-43.
85. Zhu Y-C, Zhu Y-Z, Moore PK. 2006. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol, 148:884-901.
86. Zoccali C, Mallamaci F, Tripepi G, et al. 2006. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int, 69:1253-8.